12890_2020_1121_MOESM1_ESM.docx (812.02 kB)

Additional file 1 of Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis

Download (812.02 kB)
journal contribution
posted on 08.05.2020, 03:58 by Hanyu Shi, Dawei Yin, Francesco Bonella, Michael Kreuter, Ute Oltmanns, Xuren Li, Shouchun Peng, Luqing Wei
Additional file 1: Table S1. Quality scores of observational studies in the meta-analysis based on NOS scoring system. Figure S1. Forest plot of efficacy profile (outcomes: the predicted decline in FVC% (Figure S1-a) and DLco% (Figure S1-b)) between the combined pirfenidone and acetylcysteine group and the pirfenidone alone group with only oral NAC studies. Abbreviations: FVC: forced vital capacity, PFD: pirfenidone, NAC: N-acetylcysteine. Figure S2. Forest plot of the safety profile (outcome measure: at least one side effect, Figure S2-a) and tolerability profile (outcome measure: intolerable side effects leading to treatment discontinuation, Figure S2-b) between the combined pirfenidone and acetylcysteine group and the pirfenidone alone group with only oral NAC studies. Abbreviations: PFD: pirfenidone, NAC: N-acetylcysteine. Figure S3. Forest plot of the specific safety profile (outcome measure: gastrointestinal side effects (Figure S3-a) and skin side effects (Figure S3-b)) between the combined pirfenidone and acetylcysteine group and the pirfenidone alone group with only oral NAC studies. Abbreviations: PFD: pirfenidone, NAC: N-acetylcysteine.

Funding

Natural Science Foundation of Tianjin City

History

Exports